Background Image

FHI 360-



Submit Proposal to:
Date of Issue of RFP: March 5, 2021
Date Questions from Vendor Due: March 12, 2021
Date Proposal Due: March 19, 2021
Approximate Date Vendor Contract Issued to Successful Bidder: April 9, 2021

Method of Submittal:
Respond via e-mail with attached documents in MS Word / Excel/pdf format.The vendor agrees to hold the prices in its offer firm for 30 days from the date specified for the receipt of offers, unless another time is specified in the addendum of the RFP.


Over many years of research, FHI 360 has generated substantive and convincing data showing that the doses of depot medroxyprogesterone acetate (DMPA) are greater than necessary to provide highly effective contraception for the labeled 3-month duration. The existing pharmacokinetic (serum MPA levels) and pharmacodynamic (suppression of ovulation) evidence supports the duration of effectiveness of the current subcutaneous 104 mg DMPA formulation (DMPA-SC) beyond three months. Extending the reinjection interval of DMPA-SC from 3 to 4 months (making it a 3-times-per-year product) would reduce long-term MPA exposure by 25% and reduce risk of accumulation, which would potentially shorten the delay in return to ovulation and fertility and reduce other dose-dependent side effects. Extending re-injection could also improve access to DMPA-SC in resource-constrained settings by reducing programmatic costs and opportunity costs, such as travel expenses, for users.

With support from the Children’s Investment Fund Foundation (CIFF), FHI Partners, LLC, a nonprofit subsidiary of FHI 360 is conducting several activities to establish the evidence base for and support the registration of a generic DMPA-SC as a 4-month product. The availability of such a product has the potential to improve consumer experience with a significantly lower dose, offer procurement savings that could grow to $10M per year, and alleviate supply chain bottlenecks faced with the current manufacture of Sayana Press®[1].

This scope of work (SOW) will support a two-phased, market research activity focused on user considerations for the introduction of a 4-month DMPA-SC product in Nigeria.


The goal of this market research is to assess contraceptive user perspectives on, and communication needs for, introducing a 4-month DMPA-SC product to the market for self-injection and provider administration in Nigeria.

Specific study objectives include:

  • To assess the acceptability of a 4-month DMPA-SC product (as well as other durations, including a 6-month injectable) among potential and current contraceptive injectable users
  • To assess users’ perspectives on having multiple injectable products of different durations in the market
  • To develop communication strategies/marketing messages to differentiate the 4-month product from other similar products


This is a two-phased, descriptive, and rapid qualitative market research project, including a Phase I market assessment and Phase II user-centered design (UCD) marketing workshop guided by human-centered design (HCD) principles. FHI 360 seeks the services of a design firm to lead both phases in close collaboration with the local site investigator.

  • For the Phase I market assessment, the design firm will conduct small, semi-structured and participatory focus group discussions (FGDs) with adult, female contraceptive users (current injectable users and ‘potential’ users) to generate insights into client preferences and behaviors that can help to shape product development and introduction.
    • The design firm will work closely with the site investigator to ensure that ethical standards are adhered to and that quality data are being collected in accordance with the approved protocol. They will also engage in daily debriefs during data collection to provide updates on progress, and review data capture and findings in a rolling, response-driven and iterative fashion.
  • For the Phase II UCD marketing workshop, the design firm will organize and facilitate a one-day event with potential 4-month DMPA-SC product users, drawing upon insights and artefacts generated in Phase I, and in accordance with the approved protocol, to inform ideation activities, and support development of strategic marketing initiatives for product introduction.

The design firm will be responsible for all coordination and logistical tasks related to the planning, scheduling, and successful completion of the Phase I market assessment and Phase II UCD workshop. For both phases the design firm will be responsible for ensuring proper data management, including copies of all informed consent forms, audio recordings, and any other study notes and documents. The activities will be performed in accordance with the study protocol developed by FHI Partners.  FHI Partners is also responsible for obtaining the necessary Institutional Review Board (IRB) approvals prior to study initiation.


Group Type
Phase I Market Assessment Mini FGDs Participants Per Total
2: Women 18-24 Current Injectable Users 3 Up to 3 9
Potential[2] Users 3 Up to 3 9
3: Women 25+ Current Injectable Users 3 Up to 3 9
Potential Users 3 Up to 3 9
Total Participants     36
Phase II UCD Workshop
2: Women 18-24 Current Injectable Users 4
Potential Users 4
3: Women 25+ Current Injectable Users 4
Potential Users 4
  Total Participants     24[3]
   Total Both Phases 60           


FHI Partners will award a fixed price purchase order to the selected design firm team to perform Phase I and II market research activities in Lagos, Nigeria. Timelines are contingent upon local Institutional Review Board (IRB) approval but Phase I is broadly estimated to take place over a roughly 3-week period during the months of June to August 2021 and Phase II during the month of September 2021.

All information collected shall become the exclusive property of FHI Partners.


  • Prepares site for data collection activities
    • Obtains any necessary local approvals (excludes IRB approval)
    • Works with site investigator to initiate FP clinic outreach and relationship-building for recruitment of contraceptive users for both phases
  • Ensures all design team members have current research ethics certifications prior to data collection (site investigator will support)
  • Collaborates with FHI 360 HQ staff and site investigator on refining the Phase I discussion guide and Phase II workshop facilitation guide
  • Participates in study orientations and trainings led by the site investigator and FHI 360 staff
  • Translates discussion and workshop facilitation guides, recruitment scripts, and informed consent forms into the local dialects, as necessary
  • Identifies, contacts, and recruits study participants for both phases
  • Conducts FGDs for Phase I
  • Facilitates UCD workshop for Phase II
  • Maintains complete and accurate study files
  • Maintains participant confidentiality and security of data gathered
  • Provides reimbursement to study participants in compliance with the approved protocol and maintains accurate records of disbursements and balances, as required
  • Assists in monitoring study progress including updating timelines, tracking data quality, and notifying the site investigator of adverse events
  • Leads daily debrief sessions with the site investigator during Phase I data collection and participates in collaborative synthesis sprints with site investigator and FHI 360 HQ at the end of Phase I and Phase II
  • Regularly participates in calls with FHI 360 HQ and promptly answers queries during data collection and analysis, as needed
  • Summarizes findings into a report for each phase

Location of Work

Lagos, Nigeria


  1. Phase I market assessment approach, responsive the study design laid out in the protocol, that includes a detailed recruiting strategy, schedule, and data analysis plan
  2. Translated focus group discussion guide, informed consent forms and workshop facilitation guide
  3. Pretest report with recommendations for adjustments to the focus group discussion guide, if needed.
  4. Weekly data capture share outs during Phase I [data capture mechanism(s) to be determined with input from the FHI 360 HQ study team and site investigator]
  5. A Phase I report summarizing high-level findings from data collection
  6. A Phase II UCD workshop approach, with examples of rich media assets and collateral to be employed, and facilitation guide
  7. A Phase II report summarizing high-level findings from the workshop together with recommendations for a communications strategy and targeted marketing messages
  8. An asset repository of tools used, images collected, and collateral generated during Phases I and II, as well as user-generated outputs from Phase II

You need to login to view the rest of the content. Please . Not a Member? Join Us

No Comments

Post a Comment

Password reset link will be sent to your email